Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Reuters

Jun 19

Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544166075"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544166075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544166075?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544166075","market":"nz","top_or_hot":-1,"title":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-19 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1232","symbol_name":"复合型公用事业","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL7kd4mX:1","article_id":"2544166075","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544166075","pubTimestamp":1750332486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1232":"复合型公用事业","BK0188":"融资融券","002393":"力生制药","BK0028":"国家队","00882":"天津发展","BK0239":"医药制造"},"translate_title":"天津发展控股子公司力生制药与兴业银行新协议扩大投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":0.9,"00882":0.9},"content_text":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    \n\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}